TargetGene Biotechnologies

Join our mission to engineer the next 20 years of gene editing breakthroughs - today. Pioneering novel viral and non-viral delivery technologies to truly enable in vivo genetic medicine. Built for exceptional specificity within the genome – enabling therapeutic precision and allele specific targeting.

We are scientific pioneers with unlimited potential to cure genetic disease. We are scientists and leaders on a shared mission to make innovative, curative therapies available to patients with devastating genetic diseases. We are guided by curiosity, rigor, and integrity. We are pioneers with unlimited potential to cure genetic disease. Our highly innovative, next-generation platform allows us to target any genomic sequence and develop life-changing therapies for the most challenging genetic disorders. They were developed from a proprietary collection of non-pathogenic organisms and offer gene editing tools with higher fidelity, novel functionality, reduced immune response risk, and easier delivery. Life Edit Therapeutics has joined ElevateBio’s portfolio of therapeutic, technology, and manufacturing companies and reimagined our identity. Our brand is an expression of our values, mission, and commitment to paving the way to faster, safer, more innovative gene editing therapeutics that treat diseases once thought to be incurable.

We are developing next-generation gene editing medicines to cure rare genetic diseases at their roots by correcting inborn genetic errors directly in patients’ cells. Founded in 2018 based on the scientific discoveries of Anna Cereseto’s laboratory.

Cure Genetics, is a clinical-stage biotechnology dedicated to developing first-in-class cell and gene therapies for solid tumors and genetic disorders through our innovative AIMS CAR-NKT and VELPTM AAV discovery platforms. We aim to provide effective treatment measures for patients worldwide with unmet medical needs and to become a benchmark in the global field of cell and gene therapies. Founded Cure Genetics in 2016, dedicated to developing innovative gene and cell therapies for genetic diseases and tumors. Ren is a seasoned expert in cell therapy, boasting over 20 years of experience developing and advancing cell therapy drug candidates from pre-clinical to commercial licensure across US, EU, and Japan. Ren has supported multiple IND submissions for cell therapy pipeline products to enable clinical trials and designed and led process & analytical validation programs in support of commercial registration filing. Shawn will guide the navigation of Cure Genetics' cell therapy development, leading the team to break new ground and accelerate the progress of cell therapy pipelines. We have built 4000m2 R&D, enzyme raw material manufacturing and IVD GMP manufacturing center in order to quickly promote the registration filings of our core products.

Our mission is to develop best-in-class gene therapies for people with life-threatening diseases. Our vision is to be the leader in the evolution of gene therapy and be known for superior drug development, high industry standards, extraordinary integrity and an innovative team that translates science into treatments that prolong and improve lives.

Our mission is to cure disease by writing in the code of life. We are pioneering tissue-targeted non-viral delivery technology to make genomic alterations where they are needed. The first of its kind, Gene Writing is a versatile technology platform that can permanently make small and large alterations to the human genome.